Rivaling dot-com boom, 2018 breaks record for San Diego startups raising ca...
San Diego Venture Group
The Science of Data + Healthcare
In Partnership with JLABS
An expert panel, talking about
- trends in funding
- disruptive emerging tech
- what it takes to make it as a data science innovator in healthcare
Senior Associate, DCVC Bio
Anna is a Senior Associate at DCVC Bio. Prior to DCVC, Anna was on the investment team at Monsanto Growth Ventures (MGV), the Venture Capital arm of Monsanto, which was one of the most active investors globally in agriculture. Prior to joining MGV, Anna was a long-short equity analyst at Moore Capital Management and SC Fundamental. Before that, she was an investment banking analyst in the M&A group at Centerview Partners. Anna received a BA in Economics-Mathematics from Columbia University and an MBA from Harvard Business School.
Investment Director, Illumina Ventures
Wouter is Investment Director at San Francisco-based Illumina Ventures, where he focuses on life science tools, genomics, and synthetic biology. He was at Illumina for 8 years prior to joining Illumina Ventures, where he held roles in Corporate Development, Product Development, and R&D. A physical chemist by training, he began his career in life sciences as first hire for Oxford University spin-out Oxamer, a company founded in 2003 by Lasker-award winner Prof. Sir Edwin Southern, where he contributed to the development a benchtop DNA microarray fabrication platform. After the company got acquired Oxford Gene Technology in 2005, he continued working alongside Southern leading R&D efforts into single cell gene expression analysis and novel applications for DNA microarrays. He obtained his undergraduate and Master’s degree in Chemistry from the University of Ghent, Belgium; a PhD in Chemical Engineering from the University of Newcastle, U.K; and an MBA from the University of Cambridge, U.K.
Managing Partner, Embark Ventures
Yipeng Zhao is a Managing Partner at Embark Ventures, a Los-Angeles based venture capital firm focused on early-stage “Deep-Tech” companies. We look for ambitious teams with a break-through proprietary technology which provides a highly defensible competitive advantage in transforming multi-billion dollar industries. Key focus areas including Biotech, Advanced Materials and Nanomaterials, Cyber-security and Automation. Yipeng co-founded Embark Ventures in 2017 where he manages Embark Ventures’ new investments and portfolio companies.
Yipeng started his career as a research statistician at UCSD focused on Nonparametric and Semiparametric estimation and inference problem in Econometrics. While at UCSD he spent time on the application of big data in customer behavior research and game-theoretical econometrics approach to customer behavior research. Yipeng also has extensive research experience in financial risk management and time series data analysis. After that, Yipeng joined ZMXY Global Investment, a China-based private equity investor where he has been actively involved in equity investment in both China and US. While at ZMXY Global Investment, Yipeng also helped ZMXY Global Investment set up their venture investment arm in Los Angeles as a part of the global strategy.
Ashley Van Zeeland
Vice President, Product Development, Business Operations & Systems Integration, Illumina
Dr. Van Zeeland has been leading innovative genomics research and development programs for the past 15 years, and is currently Vice President, Product Development Business Operations and Systems Integration at Illumina. Previously, she was co-founder and CEO of Cypher Genomics, a cloud-based genome interpretation company, which sold to Human Longevity, Inc. (HLI) in 2015. At HLI Dr. Van Zeeland served as Chief Technology Officer, directing the software and bioinformatics development for a large-scale genomics platform, and enabling health intelligence and related products. Prior to founding Cypher Genomics, she served as Director, Strategic Partnerships at the Scripps Translational Science Institute where she focused on novel public-private partnerships to accelerate translational research. She holds a Ph.D. in Neuroscience from the University of California, Los Angeles and MBA from the University of California, San Diego.